FIELD: medicine.
SUBSTANCE: on the basis of amino acid sequence of domain 10 of type III human fibronectin (10Fn3) obtained is group of mutant polypeptides, able to compete with natural vessel endothelium growth factor (VEGF-A) for binding with receptor VEGFR-2 (KDR), as well as pegylated forms of said polypeptides with improved pharmacokinetic characteristics. It is proposed to use novel polypeptodes and their pegylated derivatives for inhibition of VEGF-mediated biological activities, in particular in therapy of cancer diseases.
EFFECT: increase of medication efficiency.
18 cl, 31 dwg, 11 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BINDING PROTEINS INHIBITING VEGF-A RECEPTOR INTERACTION | 2009 |
|
RU2550258C2 |
| BINDING PROTEINS, INHIBITING INTERACTION OF VEGF-A RECEPTOR | 2009 |
|
RU2650765C1 |
| ANTIANGIOGENIC COMPOUNDS | 2009 |
|
RU2511420C2 |
| DNA VACCINE AGAINST PROLIFERATING ENDOTHELIAL CELLS AND USES THEREOF | 2003 |
|
RU2318019C2 |
| VEGF BINDING V9 NANOANTIBODY AND METHOD OF OBTAINING SAID ANTIBODY, V9-CODING NUCLEOTIDE SEQUENCE AND VECTOR CONTAINING SAID SEQUENCE, ENDOTHELIAL CELL PROLIFERATION INHIBITION METHOD | 2008 |
|
RU2395521C1 |
| ACTIVE ANGIOGENESIS-PREVENTING IMMUNETHERAPY | 2003 |
|
RU2329824C2 |
| COMPOSITIONS OF HUMANISED NOTCH FUSED PROTEINS AND METHODS OF TREATING | 2008 |
|
RU2532830C2 |
| HYBRID PROTEINS BASED ON HUMAN Notch3 AS TRAPS-INHIBITORS OF Notch3 SIGNAL TRANSMISSION | 2009 |
|
RU2567662C2 |
| STABLE AND SOLUBLE ANTIBODIES INHIBITING VEGF | 2016 |
|
RU2648152C2 |
| PROAPOPTOSIS PROTEINS-CONTAINING THERAPEUTIC AGENTS | 2002 |
|
RU2319709C2 |
